Machine Learning-Guided Training for Elite Athletes (MLGT) (MLGT)

June 27, 2026 updated by: Dr. Arefayne Mesfen Dessye, Debre Berhan University

A Machine Learning-Guided Training Approach to Reduce Injuries and Enhance Performance in Elite Athletes: A Prospective Cohort Evaluation

Plaintext The purpose of this study is to evaluate whether a personalized training protocol driven by machine learning can successfully reduce time-loss sports injuries and enhance athletic performance in elite athletes.

During a 9-month competitive sports season, a group of elite athletes was divided into two training

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study evaluated the efficacy of an adaptive, machine learning-driven training protocol compared to traditional athletic preparation over a full 9-month competitive sports season. The primary objective was to determine if a dynamic, technology-led approach to training load management could minimize time-loss injuries while concurrently optimizing athletic performance markers.

Participants were elite athletes randomly allocated into two parallel groups:

  1. The Experimental Group, which underwent training regimens dynamically adjusted using a machine learning algorithm that analyzed individual biomechanical data and historical workload parameters to optimize training volume and intensity.
  2. The Control Group, which followed standard, predetermined high-performance athletic training protocols typical for competitive season preparation.

Throughout the 9-month intervention period, daily tracking was maintained by technical and coaching staff. Data collection focused on the incidence, severity, and duration of all time-loss sports injuries. Concurrently, sport-specific performance parameters were periodically assessed to evaluate physical conditioning and competitive readiness. Statistical analyses were subsequently conducted to compare cumulative injury rates, total days lost to injury, and net performance adaptations between the two cohorts.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
120

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Ethiopia
    • Shewa
      • Debre Berhan, Shewa, Ethiopia, 445
        • Dr. Arefayne
      • Debre Berhan, Shewa, Ethiopia, 445
        • M Dessye

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  1. Must be a competitive, elite-level or sub-elite track and field athlete specializing in short-to-mid distance running events.
  2. Aged between 18 and 35 years old.
  3. Actively participating in structured athletic training programs for at least 2 years prior to enrollment.
  4. Free from any acute musculoskeletal injuries or medical conditions that prevent full participation in high-intensity training protocols.
  5. Capable and willing to provide written informed consent to participate in the study.

Exclusion Criteria: 1. Current or recent (within the past 3 months) major lower-limb injury or surgery that restricts maximal sprint or aerobic performance.

2. Concurrent use of performance-enhancing drugs or medications that influence metabolic or cardiovascular responses.

3. Inability to maintain consistent participation in the designated training protocols due to scheduling conflicts or travel.

4. Any underlying cardiovascular, respiratory, or systemic condition that creates a health risk during exhaustive exercise testing.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: Control Cohort
Elite adolescent sprinters who followed standard, predetermined high-performance athletic training protocols typical for competitive season preparation. This group received structured training volume and intensity matching standard athletic coaching guidelines, without any machine learning interventions or adaptive workload adjustments.
Behavioral: Adaptive Machine Learning Workload Optimization
A personalized, data-driven training intervention where athletic workloads are dynamically adjusted based on predictive modeling. The protocol continuously tracks individual physiological markers, biomechanical data, and workload history to optimize training volume and intensity. This adaptive approach aims to maximize performance gains while minimizing the risk of overtraining and injury during the competitive season.
Experimental: Algorithmic Cohort
Elite adolescent sprinters who received a personalized training protocol dynamically optimized by a machine learning algorithm. The framework evaluated individual biomechanical variables, morning heart rate variability (HRV), sleep quality, and physiological fatigue metrics to adjust training volume and intensity.
Behavioral: Adaptive Machine Learning Workload Optimization
A personalized, data-driven training intervention where athletic workloads are dynamically adjusted based on predictive modeling. The protocol continuously tracks individual physiological markers, biomechanical data, and workload history to optimize training volume and intensity. This adaptive approach aims to maximize performance gains while minimizing the risk of overtraining and injury during the competitive season.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Changes in Sprint Performance Time
Time Frame: 12 weeks
Sprint performance will be assessed using electronic timing gates to record running times over a specific distance from a stationary start. Lower times indicate improved sprint performance. Measurements will be taken at baseline and at the conclusion of the training intervention period to evaluate the impact of the workload protocols.
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Debre Berhan University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Dr. Arefayne M Dessye, PhD, Debre Berhan Univeristy

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2023

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 30, 2023

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
September 30, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 27, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 27, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 6, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 6, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 27, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • DBU-SS-2023-008
  • IRB#DBU-SS-2023-008 (Registry Identifier: ClinicalTrials.gov)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data (IPD) will not be shared publicly to maintain the confidentiality of the elite athletes involved and to protect proprietary training protocols. Aggregated study results and statistical analyses will be available through academic publication.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Athletic Injuries

Clinical Trials on Adaptive Machine Learning Workload Optimization

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings